Dirk Nagorsen

Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia

Hagop Kantarjian, Anthony S. Stein, Nicola Gökbuget et al. · New England Journal of Medicine · 2017 · 2K citations · Full text

Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study

Max S. Topp, Nicola Gökbuget, Anthony S. Stein et al. · The Lancet Oncology · 2014 · 1.2K citations

Hematological Malignancy, Lymphoid Neoplasia, Oncology +9

Targeted Therapy With the T-Cell–Engaging Antibody Blinatumomab of Chemotherapy-Refractory Minimal Residual Disease in B-Lineage Acute Lymphoblastic Leukemia Patients Results in High Response Rate and Prolonged Leukemia-Free Survival

Max S. Topp, Peter Kufer, Nicola Gökbuget et al. · Journal of Clinical Oncology · 2011 · 902 citations · Full text

Blinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemia

Nicola Gökbuget, Hervé Dombret, Massimiliano Bonifacio et al. · Blood · 2018 · 810 citations · Full text

Long-term follow-up of hematologic relapse-free survival in a phase 2 study of blinatumomab in patients with MRD in B-lineage ALL

Max S. Topp, Nicola Gökbuget, Gerhard Zugmaier et al. · Blood · 2012 · 466 citations · Full text